Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

KPV

Lys-Pro-Val, α-MSH (11-13)

Quick Stats
Studies 104
Trials 57
2021 pubmed 56 citations

Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial.

Meijerink. Martijn R MR; Ruarus. Alette H AH; Vroomen. Laurien G P H LGPH; Puijk. Robbert S RS; Geboers. Bart B; Nieuwenhuizen. Sanne S; van den Bemd. Bente A T BAT; Nielsen. Karin K; de Vries. Jan J J JJJ; van Lienden. Krijn P KP; Lissenberg-Witte. Birgit I BI; van den Tol. M Petrousjka MP; Scheffer. Hester J HJ

Practical Outcomes

  • There are no actionable takeaways for kpv use or health‑optimization protocols; the results apply only to a specific clinical setting for tumor ablation.

Summary

The paper studies a cancer‑treatment technique (irreversible electroporation) for liver metastases, not the peptide kpv, so it offers no useful info for biohackers interested in kpv or self‑experiments.

Abstract

Background Irreversible electroporation (IRE), an ablative technique that uses high-voltage electrical pulses, has shown promise for eradicating tumors near critical structures, including blood vessels and bile ducts. Purpose To investigate the efficacy and safety of IRE for colorectal liver metastases (CRLMs) unsuitable for resection or thermal ablation because of proximity to critical structures and for further systemically administered treatments. Materials and Methods Between June 2014 and November 2018, participants with fluorine 18 (<sup>18</sup>F) fluorodeoxyglucose (FDG) PET-avid CRLMs measuring 5.0 cm or smaller, unsuitable for partial hepatectomy and thermal ablation, underwent percutaneous or open IRE (ClinicalTrials.gov identifier: NCT02082782). Follow-up included tumor marker assessment and <sup>18</sup>F-FDG PET/CT imaging. For the primary end point to be met, at least 50% of treated participants had to be alive without local tumor progression (LTP) at 12 months, defined as LTP-free survival. Secondary aims were safety, technical success, local control allowing for repeat procedures, disease-free status, and overall survival. Results A total of 51 participants (median age, 67 years [interquartile range, 62-75 years]; 37 men) underwent IRE. Of these 51 participants, 50 with a total of 76 CRLMs (median tumor size, 2.2 cm; range, 0.5-5.4 cm) were successfully treated in 62 procedures; in one participant, treatment was stopped prematurely because of pulse-induced cardiac arrhythmia. With a per-participant 1-year LTP-free survival of 68% (95% CI: 59, 84) according to competing risk analysis, the primary end point was met. Local control following repeat procedures was achieved in 74% of participants (37 of 50). Median overall survival from first IRE was 2.7 years (95% CI: 1.6, 3.8). Twenty-three participants experienced a total of 34 adverse events in 25 of the 62 procedures (overall complication rate, 40%). One participant (2%), who had an infected biloma after IRE, died fewer than 90 days after the procedure (grade 5 adverse event). Conclusion Irreversible electroporation was effective and relatively safe for colorectal liver metastases 5.0 cm or smaller that were unsuitable for partial hepatectomy, thermal ablation, or further systemic treatment. &#xa9;&#x2009;RSNA, 2021 <i>Online supplemental material is available for this article.</i> See also the editorial by Goldberg in this issue.

Study Information

Provider

pubmed

Year

2021

Date

2021-03-16T00:00:00.000Z

DOI

10.1148/radiol.2021203089

Citations

56

References

24